论文部分内容阅读
呼吸道合胞病毒(RSV)是在世界范围内引起婴幼儿下呼吸道感染的重要病毒之一,WHO要求对RSV要严加监控。RSV是副粘病毒科肺炎病毒属的单股负链非节段性RNA病毒。RSV疫苗的研制已有40多年的历史,但至今未被批准使用其疫苗。RSV膜表面融合蛋白F和黏附蛋白G两种糖蛋白,是激发机体产生保护性抗体的最主要的病毒抗原,亚单位疫苗的开发主要针对这两个蛋白。目前研究的有纯化的F糖蛋白(PFP)、BBG2Na、嵌合型F-G糖蛋白及纯化的F、G和基质蛋白M。本文就目前国内外所研究的RSV亚单位疫苗作一综述。
Respiratory syncytial virus (RSV) is one of the most important viruses that cause lower respiratory tract infections in infants and young children worldwide. The WHO requires that RSV be strictly monitored. RSV is a single-stranded negative non-segmented RNA virus of the Paramyxoviridae pneumonia virus genus. The RSV vaccine was developed over 40 years ago but has not been approved for its use to date. RSV membrane surface fusion protein F and adhesion protein G glycoprotein, is to stimulate the body to produce protective antibodies the most important viral antigens, subunit vaccine developed mainly for these two proteins. Currently studied are purified F glycoprotein (PFP), BBG2Na, chimeric F-G glycoprotein and purified F, G and matrix protein M. This article reviews the current research on RSV subunit vaccines at home and abroad.